CORRECTED-Sanofi drug Dupixent wins U.S. FDA approval to treat asthma [Reuters]
Sanofi - American Depositary Shares (SNY)
US:NYSE Investor Relations:
sanofi.com/en/investors
Company Research
Source: Reuters
Sanofi drug Dupixent wins FDA approval to treat asthma | Reuters 1 Min Read (Reuters) - France’s Sanofi SA said on Friday eczema drug Dupixent was approved by the U.S. Food and Drug Administration as an additional maintenance therapy in patients with two types of asthma. Dupixent, co-developed with U.S.-based Regeneron, received approval to treat patients with eosinophilic asthma, a rare form of the disease, and those dependent on anti-inflammatory steroids. The drug acts by restraining proteins responsible for the inflammation of airways of the lungs, the root cause of asthma. Dupixent was launched in the United States in April 2017 for the treatment of moderate-to-severe eczema in adults. The drug, a key revenue driver for Sanofi, had worldwide sales of 176 million euros ($202.5 million) in the second quarter of 2018, of which 151 million euros came from the United States. The drugmaker is also co-developing Dupixent for at least seven other conditions including pediatric asthma, ch
Show less
Read more
Impact Snapshot
Event Time:
SNY
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
---|---|---|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
Last Price | ||
VWAP | ||
High:
|
Max Up |
High:
|
Low:
|
Max Down |
Low:
|
%
|
Post news range |
%
|
|
Price change |
|
|
Price Change Percentage |
|
|
S&P 500 (SPX) |
|
%
|
Volume ratio |
%
|
Volume | ||
Ticks | ||
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
SNY alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
SNY alerts
High impacting Sanofi - American Depositary Shares news events
Weekly update
A roundup of the hottest topics
SNY
News
- Cannabis Testing Services Market Report 2024, Featuring Saskatchewan Research Council (SRC), Eurofins Scientific, PharmLabs, Steep Hill, CW Analytical, GreenLeaf Lab, Praxis Laboratory and SGS Canada [Yahoo! Finance]Yahoo! Finance
- United States Self-Monitoring Blood Glucose Devices Market Research 2023-2032: SMBG Devices and CGM Systems Surge - The Shift from Traditional Blood Glucose Meters [Yahoo! Finance]Yahoo! Finance
- Japan approves AstraZeneca-Sanofi drug for prevention of RSV disease in infants [Seeking Alpha]Seeking Alpha
- Indian shares set to open little changed as global rally comes to a halt [Reuters]Reuters
- ReportLinker Reveals Key Insights About Players and Coverage in Latest Combination Vaccine Market Analysis [Yahoo! Finance]Yahoo! Finance
SNY
Sec Filings
- 3/20/24 - Form 6-K
- 3/15/24 - Form S-8
- 2/27/24 - Form 6-K
- SNY's page on the SEC website